Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNMBP antisense RNA 1 (DNMBP-AS1) is a long non-coding antisense RNA molecule transcribed from the DNMBP gene region but does not encode a protein. It functions primarily in the post-transcriptional regulation of gene expression, acting as a regulatory sponge for microRNAs like miR-6766-3p. In prostate cancer, DNMBP-AS1 is significantly upregulated and contributes to cancer cell proliferation, migration, and invasion, in part by stabilizing the expression of lysocardiolipin acyltransferase 1 (LCLAT1) through interaction with the RNA-binding protein ELAVL1. DNMBP-AS1 is considered a promising therapeutic target for RNA-based interventions and may serve as a biomarker for certain cancers, although its clinical utility remains under investigation.
Nucleic acid-based inhibition (e.g., antisense oligonucleotides binding to DNMBP-AS1, siRNA-mediated gene silencing); Sponging microRNA (miR-6766-3p)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNMBP antisense RNA 1 (DNMBP-AS1).